LIVN

LivaNova has delivered a 59.9% gain over the past three years, which naturally puts attention on whether that move lines up with the cash the business is expected to generate.

LivaNova (LIVN) has drawn fresh attention after recent trading left the share price near US$75. Investors are weighing double digit annual revenue and net income growth against mixed returns across different time frames.

Tributary Capital Management released its second-quarter 2026 investor letter for “Multi Cap Core Equity Strategy”. You can download a copy of the letter here.

The insider sold 1,650 shares but still retains nearly 8,000 shares.

LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier.

LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record quarterly revenue and significantly higher profitability, supported by demand for its Essenz heart-lung machine and a new supply agreement with Thermo Fisher Scientific.

Record quarterly revenue driven by Essenz upgrades and oxygenator market share gains.

LivaNova PLC (LIVN) delivers 9.8% constant currency revenue growth, raises full-year outlook, and secures key oxygenator supply agreement.

While the top- and bottom-line numbers for LivaNova (LIVN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.